-
MIMEDX study published on tissue allograft immunomodulatory effects
-
MIMEDX publishes interim trial results showing wound care product benefit
-
MIMEDX responds to Medicare fee schedule changes for 2026
-
MiMedx Group (MDXG) Tops Q3 EPS by 9c
-
MIMEDX launches EPIXPRESS wound care product
-
MiMedx Group (MDXG) PT Raised to $12 at Cantor Fitzgerald
-
MiMedx Group (MDXG) Tops Q2 EPS by 5c
-
MIMEDX supports proposed Medicare skin substitute reimbursement changes
-
Cantor Fitzgerald Reiterates Overweight Rating on MiMedx Group (MDXG)
-
After-hours movers: FB Financial, MiMedx Group, Organogenesis, and more
-
Organogenesis Holding (ORGO), Smith & Nephew (SNN) & Integra LifeSciences (IART) Also Fall on CMS Publication
-
MiMedx Group (MDXG), Organogenesis (ORGO) Shares Fall After CMS Proposal to Cut Spending
-
MiMedx Group (MDXG) Reports In-Line Q1 EPS
-
Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer
-
MiMedx Group (MDXG) Tops Q4 EPS by 1c
-
MiMedx Group (MDXG) Files Patent Infringement Lawsuit Against Surgenex
-
MiMedx Group (MDXG) PT Raised to $16 at Mizuho
-
MiMedx Group (MDXG) Tops Q3 EPS by 3c
-
MiMedx Group (MDXG) Reports In-Line Q2 EPS
-
MiMedx Group (MDXG) Launches HELIOGEN Fibrillar Collagen Matrix
-
Cassava Sciences (SAVA): Remi Barbier resigns as President and CEO and from the Board of Directors
-
Cantor Fitzgerald Starts MiMedx Group (MDXG) at Overweight
-
MiMedx Group (MDXG) Appoints Kim Moller as Chief Commercial Officer

